Different topoisomerase IIa protein expression patterns affect prognosis in tongue squamous cell carcinoma: A quantitative digital image analysis study

Oral Surgery

Volumn 1, Issue 3, 2008, Pages 117-124

  Machaira, A ^a   Tsiambas, E ^b   Goula, K ^b   Chrysomali, E ^c   Nikolatou, O ^c   Manaios, L ^b   Rapidis, A D ^a   Karameris, A ^b   Patsouris, E ^d  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b 417VAHospital ^*  (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Image analysis; Immunohistochemistry; Squamous cell carcinoma of the tongue; Topoisomerase

Indexed keywords

EID: 79551502832     PISSN: 17522471     EISSN: 1752248X     Source Type: Journal    
DOI: 10.1111/j.1752-248X.2008.00033.x     Document Type: Article

References (35)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer.N Engl J Med 1993;328:184-94.
2. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN)2: chromosomal aberrations. Oral Oncol 2000;36:311-27.
3. Viswanathan H,Wilson JA. Alcohol-the neglected risk factor in head and neck cancer. Clin Otolaryngol Allied Sci 2004;29:295-300.
4. Veltman JA, Bot FJ, Huynen FC, Ramaekers FC, Manni JJ, Hopman AH. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol 2000;18:1644-51.
5. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990;1:199-206.
6. Duchrow M, Gerdes J, Schluter C. The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif 1994;27:235-42.
7. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2002;182:311-22.
8. Davies L, Hardin NJ, Beatty BG. Can ki 67 predict recurrence ofNOsquamous cell carcinoma of the tongue? Ann Otol Rhinol Laryngol 2006;115: 12-7.
9. Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehulsing M, Eckel HE. Prognostic significance of ki 67 (MIB-1), PCNA, and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 1999;35:583-9.
10. Bhargava R, Lal P, Chen B. HER2/neu and topoisomerase II gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.AmJ Clin Pathol 2005;123:889-95.
11. Heck MM, Earnshaw WC. Topoisomerase IIa, a specific marker for cell proliferation. J Cell Biol 1986;103:2569-81.
12. Hartwell LH,Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-34.
13. Mueller RE, Parkes PK, Andrulis I, O'Malley FP. Amplification of the TOPO2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004;39:288-97.
14. Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M. Immunohistochemical expression of topoisomerase IIa and multidrug resistance-associated protein, plus chemosensitivity testing as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 2001;21:2925-32.
15. Li J, Chen W, Zhang P, Li N. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma.World J Surg Oncol 2006;4:41.
16. Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother 2005;6:85-92.
17. Brustmann H. Immunohistochemical detection of human telomerase reserve transcriptase (h-TERT), topoisomerase IIa expression and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. Int J Gynecol Pathol 2005;24:192-6.
18. Bildric K, Ten N, Ozalp SS, Yalcin OT, Yilmaz V. Prognostic significance of DNA topoisomerase IIa (KiS1) immunoexpression in endometrial carcinoma. Eur J Gynaecol Oncol 2002;23:540-44.
19. Tanner M, Hollmen M, Juntilla TT, Kapanen AI, Tommola S, Soini Y et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-78.
20. Tsiambas E, Alexopoulou D, Lambropoulou S, Gerontopoulos K, Karakitsos P, Karameris A. Targeting Topoisomerase IIa in endometrial adenocarcinoma: a combined chromogenic in situ hybridization and immunohistochemistry study based on tissue microarrays. Int J Gynecol Cancer 2006;16:1424-31.
21. Cho YS, Kim MJ. Expression of multidrug resistance-related genes in oral squamous cell carcinomas. Oral Oncol 2001;37:652-9.
22. Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M. Immunohistochemical study of DNA topoisomerase I,DNA topoisomerase II alpha, p53, and Ki67 in oral preneoplastic lesions and oral squamous cell carcinomas.HumPathol 2004;35:745-51.
23. Mattila R, Alanen K, Syrjanen S. Immunohistochemical study on topoisomerase II alpha, Ki 67 and cytokeratin-19 in oral lichen planus lesions. Arch Dermatol Res 2007;298:381-8.
24. Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C, Adamopoulos G. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. Anticancer Res 2000;20:177-82.
25. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos Aet al.DNA Topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-43.
26. Tsiambas E, Karameris A, Tiniakos DG, Karakitsos P. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. Pancreatology 2007;7:45-52.
27. Gonzalez de Mejia E, Song YS, Ramirez-Mares MV, Kobayashi H. Effect of yerba mate (ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation. J Agric Food Chem 2005;53:1966-73.
28. Fenner M,Wehrhan F, Jehle M, Amman K, Radespiel-Troger M, Grabenbauer Get al. Restricted-expressed proliferation-associated protein (Repp86) expression in squamous cell carcinoma of the oral cavity. Strahlenther Onkol 2005;181:755-61.
29. Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.AmJ Clin Pathol 2001;115:814-22.
30. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy.AmJ Clin Pathol 2004;121:620-30.
31. Tsiambas E, Stavrakis I, Lazaris AC, Karameris A, Patsouris E. Evaluation of epidermal growth factor receptor gene and chromosome 7 alterations in squamous cell carcinoma of the larynx, using chromogenic in situ hybridization on tissue microarrays. J Laryngol Otol 2007;121:563-70.
32. Shutter J, Atkins KA, Ghartey K, Herzog TJ. Clinical applications of immunohistochemistry in gynecological malignancies. Int J Gynecol Cancer 2007;17:311-5.
33. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos Ket al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006;7:283-29.
34. Sakurai K, Urade M, Noguchi K, Hashitani S, Takaoka K, Segawa E et al. Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma. Head Neck 2007;29:1002-9.
35. Kitahara H, Kawashiri S, Kato K, Ohara T, Yoshizawa K, Nozaki S et al. Immunohistochemical expressions of E-cadherin and b-catenin correlate with the invasion, metastasis and prognosis of oral squamous cell carcinoma. Oral Surg 2008;1:28-34.